FLT3
FLT3(FMS样酪氨酸激酶3)
FLT3 (FMS-like tyrosine kinase 3) is a cytokine receptor which belongs to the receptor tyrosine kinase class III and plays a role in cell survival, proliferation, and differentiation.
FLT3 相关产品(91)
- GC11455SilvestrolCAS: 697235-38-4纯度: >98.00%
Silvestrol 是一种真核翻译起始因子 4A (eIF4A) 抑制剂,从 Agave americana Linn 中分离出来。Silvestrol 诱导自噬和半胱天冬酶介导的细胞凋亡。
- GC14396Ponatinib (AP24534)CAS: 943319-70-8纯度: >99.00%
Ponatinib (AP24534)是一种多靶点酪氨酸激酶抑制剂,可抑制Abl(IC 50 =0.37nM),PDGFRα(IC 50 =1.1nM),VEGFR2(IC 50 =1.5nM),FGFR1(IC 50 =2.2nM)和Src(IC 50 =5.4nM)的活性。
- GC15779Cabozantinib (XL184, BMS-907351)CAS: 849217-68-1纯度: >99.50%
Cabozantinib (XL184,BMS-907351) 是一种新型 MET 和 VEGFR2 抑制剂,可同时抑制转移、血管生成和肿瘤生长。
- GC12145ENMD-2076 L-(+)-Tartaric acidCAS: 1291074-87-7纯度: >98.50%
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂,对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。
- GC13547Dovitinib (TKI-258, CHIR-258)CAS: 405169-16-6纯度: >98.00%
Dovitinib (TKI-258, CHIR-258)是一种高效,具有口服活性和安全药代动力学特性的小分子多激酶抑制剂,作用于FLT3、KIT和FGFR等靶点,IC 50 值分别为1、2和8-9nM。
- GC14007DCC-2036 (Rebastinib)CAS: 1020172-07-9纯度: >99.50%
An orally bioavailable tyrosine kinase inhibitor
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC10035 | TG101209 | 936091-14-4 | >99.50% | |
An inhibitor of JAK2, FLT3, RET, and JAK3 | ||||
| GC10914 | AST 487 | 630124-46-8 | >99.00% | |
A multi-kinase inhibitor | ||||
| GC11455 | Silvestrol | 697235-38-4 | >98.00% | |
Silvestrol 是一种真核翻译起始因子 4A (eIF4A) 抑制剂,从 Agave americana Linn 中分离出来。Silvestrol 诱导自噬和半胱天冬酶介导的细胞凋亡。 | ||||
| GC12058 | TCS 359 | 301305-73-7 | >99.50% | |
A cell-permeable FLT3 inhibitor | ||||
| GC12064 | SB1317 | 937270-47-8 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14396 | Ponatinib (AP24534) | 943319-70-8 | >99.00% | |
Ponatinib (AP24534)是一种多靶点酪氨酸激酶抑制剂,可抑制Abl(IC 50 =0.37nM),PDGFRα(IC 50 =1.1nM),VEGFR2(IC 50 =1.5nM),FGFR1(IC 50 =2.2nM)和Src(IC 50 =5.4nM)的活性。 | ||||
| GC14592 | KW 2449 | 1000669-72-6 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC15307 | SU5416 | 204005-46-9,194413-58-6 | >98.00% | |
SU5416 是一种有效的小分子血管内皮生长因子受体 (VEGFR) 抑制剂。 | ||||
| GC15779 | Cabozantinib (XL184, BMS-907351) | 849217-68-1 | >99.50% | |
Cabozantinib (XL184,BMS-907351) 是一种新型 MET 和 VEGFR2 抑制剂,可同时抑制转移、血管生成和肿瘤生长。 | ||||
| GC16391 | Amuvatinib (MP-470, HPK 56) | 850879-09-3 | >98.00% | |
A multi-targeted RTK inhibitor | ||||
| GC17033 | Lestaurtinib | 111358-88-4 | >98.00% | |
A potent JAK2 and PRK1 kinase inhibitor | ||||
| GC17958 | Linifanib (ABT-869) | 796967-16-3 | >98.00% | |
A dual VEGFR and PDGFR family kinase inhibitor | ||||
| GC10638 | AT9283 | 896466-04-9 | >99.50% | |
A broad spectrum kinase inhibitor | ||||
| GC11057 | LY2801653 | 1206799-15-6 | >98.00% | |
A MET kinase inhibitor | ||||
| GC11205 | 5'-Fluoroindirubinoxime | 861214-33-7 | >98.00% | |
An inhibitor of FLT3 kinase | ||||
| GC12145 | ENMD-2076 L-(+)-Tartaric acid | 1291074-87-7 | >98.50% | |
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂,对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。 | ||||
| GC12178 | G-749 | 1457983-28-6 | >98.00% | |
An FLT3 kinase inhibitor | ||||
| GC12251 | Tandutinib (MLN518) HCl | - | - | |
FLT3 inhibitor,potent and selective | ||||
| GC13547 | Dovitinib (TKI-258, CHIR-258) | 405169-16-6 | >98.00% | |
Dovitinib (TKI-258, CHIR-258)是一种高效,具有口服活性和安全药代动力学特性的小分子多激酶抑制剂,作用于FLT3、KIT和FGFR等靶点,IC 50 值分别为1、2和8-9nM。 | ||||
| GC13848 | LY2784544 | 1229236-86-5 | >99.50% | |
Potent inhibitor of JAK2 | ||||
| GC14007 | DCC-2036 (Rebastinib) | 1020172-07-9 | >99.50% | |
An orally bioavailable tyrosine kinase inhibitor | ||||
| GC14582 | SU5614 | 1055412-47-9 | - | |
A multi-kinase inhibitor | ||||
| GC14906 | Crenolanib (CP-868596) | 670220-88-9 | >99.50% | |
An inhibitor of PDGFRα/β and FLT3 | ||||
| GC14974 | AMG 925 | 1401033-86-0 | >98.00% | |
A dual inhibitor of FLT3 and Cdk4 | ||||
